Viking Therapeutics Reaches Key Milestone in VK2735 Study
78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity
Enrollment Completed Ahead of Schedule and Above Target Size, Indicating Strong Interest in VK2735
Viking Therapeutics, Inc. (NASDAQ: VKTX), a pioneering clinical-stage biopharmaceutical company focusing on innovative therapies for metabolic and endocrine disorders, has successfully concluded patient enrollment for its Phase 3 VANQUISH-1 clinical trial. This trial aims to evaluate the dual agonist VK2735, administered via subcutaneous injection, looking into its effectiveness in treating obesity.
The VANQUISH-1 study is a randomized, double-blind, placebo-controlled, multi-center trial designed to evaluate VK2735 over a span of 78 weeks. Approximately 4,650 adult participants meeting certain weight-related criteria were enrolled. These adults, either classified as obese (BMI ?30 kg/m2) or overweight (BMI ?27 kg/m2) with at least one weight-related co-morbidity, were randomly assigned to one of four treatment groups receiving varying dosages of VK2735 or a placebo.
The primary objective of this trial is to assess the percentage change in body weight from the baseline after 78 weeks of treatment in participants taking VK2735 compared to those on placebo. Additionally, secondary endpoints will track different safety and efficacy measures, including the percentage of participants achieving weight reductions of ?5%, ?10%, ?15%, and ?20%.
Brian Lian, Ph.D., the chief executive officer of Viking, expressed excitement over the swift completion of enrollment, noting that the trial surpassed initial enrollment targets, which indicates a high demand for new treatment options for obesity beyond existing solutions. Viking Therapeutics is also focused on the concurrent Phase 3 VANQUISH-2 study, which targets type 2 diabetes patients who are either obese or overweight.
Viking Therapeutics earlier shared promising findings from the Phase 2 VENTURE study involving VK2735. Results indicated a considerable weight reduction in participants at a statistically significant level when compared to the placebo group. On average, those receiving VK2735 experienced a weight reduction as significant as 14.7%, with most adverse effects being mild to moderate, ensuring participant safety and tolerability across the board.
Understanding GLP-1 and GIP Agonists
The GLP-1 receptor activation plays a pivotal role in lowering glucose levels, reducing appetite, and enhancing insulin sensitivity, especially relevant for patients with type 2 diabetes and obesity. Notably, medications like Semaglutide, which has received FDA approval and is commercially available under various names, exemplify the efficacy of GLP-1 receptor agonists. Innovatively, further research into coactivating the GIP receptor alongside GLP-1 receptor activation has shown promise, as evidenced by Tirzepatide's approval by the FDA.
About Viking Therapeutics
Viking Therapeutics is dedicated to developing groundbreaking therapies addressing metabolic and endocrine health challenges. With two promising programs currently undergoing clinical trials, the company is leveraging its expertise in metabolism. Their flagship program VK2735 is in advanced clinical evaluation stages, with earlier phase trials indicating a strong safety profile and clinical benefits. In addition, a novel oral formulation of VK2735 is also being explored. Another important development is VK2809, which targets lipid and metabolic disorders. Viking's innovative approach includes research into dual amylin and calcitonin receptor agonists and the novel VK0214 molecule for addressing rare diseases.
To find out more about Viking Therapeutics, their ongoing research, and latest updates, please visit www.vikingtherapeutics.com.
Frequently Asked Questions
What is VK2735?
VK2735 is a dual agonist targeting GLP-1 and GIP receptors designed to treat obesity.
What phase is the VANQUISH-1 trial currently in?
The VANQUISH-1 trial is in Phase 3, focusing on the effectiveness of VK2735.
What are the main outcomes being measured in the trial?
The primary outcome is the percent change in body weight after 78 weeks of treatment.
When do we expect results from the VANQUISH studies?
Results from the VANQUISH-1 study will follow the completion of participant treatment after 78 weeks.
Is VK2735 well-tolerated in clinical trials?
Yes, previous trials showed VK2735 had a favorable safety and tolerability profile.
